A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease
Abstract
INTRODUCTION: Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease. These drugs have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 years old since they are about as effective as levodopa but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists could have peripheral and central side-effects which are often the reason for the discontinuation of the treatment. AREAS COVERED: This article presents an overview of the efficacy and the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease. EXPERT OPINION: Beyond the new generation non ergot dopamine agonists, no strong evidences allow the choice of a specific dopamine agonists for Parkinson 's disease treatment and by now dopamine agonists treatment should be tailored on specific adverse events profile.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prolonged RT and MT in PD patients with bradykinesia and rigidity have been attributed to rigidity due to abnormal basal ganglia system.
“These studies attributed the prolonged RT and MT in this kind of PD patients to the rigidity due to abnormal basal ganglia system [2, 6–9, 42].”
From Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease (2019) · cites this paper as [2]
Lack of dopamine results in slower movements that have characteristics similar to the minimum-jerk trajectory.
“Lack of dopamine has been shown to result in slower movements that had the similar characteristics of the MJT [2, 8, 41, 42].”
From Evaluation of tremor interference with control of voluntary reaching movements in patients with Parkinson's disease (2019) · cites this paper as [2]
Cites
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662 · see citing works
Gastric emptying time and gastric motility in patients with Parkinson's disease
Hardoff, R., Sula, M., Tamir, A., Soil, A., Front, A., Badarna, S., Honigman, S., & Giladi, N. (2001) · Movement Disorders · doi:10.1002/mds.1203 · Cited by 248 · see citing works
Sleepiness in Parkinson's disease: A controlled study
Brodsky, M. A., Godbold, J., Roth, T., & Olanow, C. W. (2003) · Movement Disorders · doi:10.1002/mds.10429 · Cited by 169 · see citing works
Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years
Goetz, C. G., Stebbins, G. T., & Ouyang, B. (2011) · Movement Disorders · doi:10.1002/mds.23835 · Cited by 91 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hu, Z., Hao, M., Xu, S., Xiao, Q., & Lan, N. (2019) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-019-0505-0 · Cited by 38 · see citing works
1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
Ortíz de Zárate, A., Pérez-Torralba, M., Bonet Isidro, I., López, C., Claramunt, R. M., Martínez-Casanova, D., Sánchez-Vera, I., Jiménez-González, J., & Lavandera, J. L. (2021) · Antioxidants · doi:10.3390/antiox10101584 · Cited by 11 · see citing works
- Authors
- Ceravolo, R., Rossi, C., Del Prete, E., & Bonuccelli, U.
- Affiliations
- University of Pisa (IT)
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- Corresponding author
- Bonuccelli, Ubaldo
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-01-20
- Volume
- 15
- Issue
- 2
- Pages
- 181-198
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2265060034
- Cited by
- 44
- References
- 4
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 1 · 2016: 2
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- dopamine agonists, Parkinson's disease, adverse drug reactions, levodopa, motor complications, treatment discontinuation, drug selection
- MeSH terms
- Age Factors, Aged, Animals, Antiparkinson Agents, Drug Therapy, Combination, Humans, Levodopa, Parkinson Disease, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
